Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition.
暂无分享,去创建一个
N. Tunariu | M. Germuska | N. deSouza | T. Yap | J. D. de Bono | J. Barriuso | C. Waghorne | J. Li | D. Harris | S. Frentzas